Amylyx Pharmaceuticals Förvaltning
Förvaltning kriterier kontrolleras 4/4
Amylyx Pharmaceuticals VD är Josh Cohen, utsedd i Jan 2013, har en mandatperiod på 13.58 år. totala årliga ersättningen är $ 2.72M, bestående av 25.2% lön 74.8% bonusar, inklusive företagsaktier och optioner. äger direkt 3.22% av företagets aktier, värda $ 86.69M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 5.6 år respektive 5.5 år.
Viktig information
Josh Cohen
Verkställande direktör
US$2.7m
Total ersättning
| VD-lön i procent | 25.23% |
| Anställning som VD | 13.6yrs |
| Ägande av VD | 3.2% |
| Ledningens genomsnittliga anställningstid | 5.6yrs |
| Styrelsens genomsnittliga mandatperiod | 5.5yrs |
Senaste uppdateringar av ledningen
Recent updates
Seeking Alpha • Aug 07
Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild
Summary Amylyx Pharmaceuticals (AMLX) is transitioning from its ALS legacy to a late-stage endocrine company, with avexitide as its lead asset. AMLX's $250.8M cash runway extends into 2028, supporting LUCIDITY Phase 3 readout, regulatory submission, and potential 2027 launch without near-term financing risk. LUCIDITY's pivotal trial targets post-bariatric hypoglycemia, a large orphan market with no approved therapies; topline results expected late August or early September 2026. Avexitide's competitive lead, regulatory designations, and a long-acting follow-on candidate position AMLX for first-mover advantage and franchise expansion if LUCIDITY succeeds. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 06
AMLX: Q3 LUCIDITY Outcome Will Shape View On Undervalued Opportunity
Amylyx Pharmaceuticals' updated analyst price target of $25.56, up from $24.40, reflects analysts' focus on the upcoming Phase 3 LUCIDITY readout for avexitide in post bariatric hypoglycemia and the related sales potential cited in recent research. Analyst Commentary Recent research on Amylyx Pharmaceuticals centers on the Phase 3 LUCIDITY study of avexitide in post bariatric hypoglycemia, with several firms updating their price targets and framing both upside potential and execution risks around this single pivotal catalyst.Uppdatering av berättelse • Jul 10
AMLX: Phase 3 LUCIDITY Readout Will Drive View On Undervalued Potential
The analyst fair value estimate for Amylyx Pharmaceuticals has been adjusted from $22.20 to $24.40 as analysts reference higher Street price targets, including Guggenheim's move to $40 and the stock's inclusion as a "Best Idea." This is supported by expectations around the upcoming Phase 3 LUCIDITY readout for avexitide in post-bariatric hypoglycemia and the potential of the $6b+ US PBH market. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals focuses heavily on the upcoming Phase 3 LUCIDITY readout for avexitide in post-bariatric hypoglycemia, with valuation views closely tied to how analysts frame the opportunity in the US PBH market and the stock's execution risks around this catalyst.
Uppdatering av berättelse • Jun 26
AMLX: Upcoming PBH Phase 3 Readout Will Drive Bullish Repricing
Amylyx Pharmaceuticals' updated analyst price target has shifted from about $32.63 to roughly $37.58, with analysts citing the stock's inclusion on select "Best Idea" lists and expectations around upcoming LUCIDITY trial results as key reasons for the change. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals highlights a cluster of upbeat views ahead of the LUCIDITY Phase 3 readout for avexitide in post-bariatric hypoglycemia.Ny berättelse • Apr 02
Bullish View That Future PBH Therapy Breakthrough Will Underpin Long Term Upside Potential
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals focuses on developing therapies for endocrine and neurodegenerative conditions, with a current emphasis on post bariatric hypoglycemia and ALS. What are the underlying business or industry changes driving this perspective?
Ny berättelse • Mar 19
Post Bariatric Hypoglycemia Setbacks Will Pressure Earnings Before Long Term Endocrine Potential Emerges
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on treatments for endocrine conditions such as post bariatric hypoglycemia and neurodegenerative diseases including ALS and Wolfram syndrome. What are the underlying business or industry changes driving this perspective?Ny berättelse • Mar 05
PBH Franchise And Neurodegeneration Pipeline Will Support A Stronger Future Business Model
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for endocrine disorders and neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Analysartikel • Sep 01
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Amylyx Pharmaceuticals...Analysartikel • May 10
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • Apr 03
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking
Those holding Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares would be relieved that the share price has rebounded...Seeking Alpha • Feb 24
Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery
Summary AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. The company purchased late-stage assets from a bankrupt company and are running them through trials. Considerable risks remain as to the market, and whether AMLX can overcome its streak of bad luck. Read the full article on Seeking AlphaAnalysartikel • Dec 19
Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding
The Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has softened a substantial 26% over the previous 30 days...Analysartikel • Dec 10
Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Nov 25
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Summary The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy is expected in mid-2025, determining the program's future. Financially, Amylyx has $234.4 million in cash, enough to fund operations into 2026, but may need to raise additional funds in 2025. Avexitide, an acquired GLP-1 receptor antagonist for patients with post-bariatric hypoglycemia, is expected to start a phase 3 study in Q1 of 2025, with data expected in 2026. Read the full article on Seeking AlphaAnalysartikel • Nov 04
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 81% gain in the last...Analysartikel • Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 37% gain in the last...Seeking Alpha • Jun 25
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Summary Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025. The company could possibly acquire rights to phase 3 ready GLP-1 asset Avexitide; This depends upon meeting certain conditions under this agreement, including a favorable ruling from the Texas Bankruptcy Court. Read the full article on Seeking AlphaAnalysartikel • Apr 25
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Unfortunately for some shareholders, the Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has dived 31% in the...Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$152m |
| Mar 31 2026 | n/a | n/a | -US$150m |
| Dec 31 2025 | US$3m | US$686k | -US$145m |
| Sep 30 2025 | n/a | n/a | -US$149m |
| Jun 30 2025 | n/a | n/a | -US$188m |
| Mar 31 2025 | n/a | n/a | -US$219m |
| Dec 31 2024 | US$6m | US$686k | -US$302m |
| Sep 30 2024 | n/a | n/a | -US$259m |
| Jun 30 2024 | n/a | n/a | -US$166m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$7m | US$621k | US$49m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$149m |
| Dec 31 2022 | US$7m | US$539k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$184m |
| Jun 30 2022 | n/a | n/a | -US$153m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$1m | US$418k | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$68m |
| Dec 31 2020 | US$671k | US$370k | -US$42m |
Ersättning vs marknad: Josh s total kompensation ($USD 2.72M ) är under genomsnittet för företag av liknande storlek på US marknaden ($USD 6.93M ).
Ersättning vs inkomst: Ersättningen från Josh har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
Josh Cohen (34 yo)
13.6yrs
Anställning
US$2,719,807
Kompensation
Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 13.6yrs | US$2.72m | 3.22% $ 86.7m | |
| Co-CEO & Director | 13.6yrs | US$2.72m | 3.22% $ 86.7m | |
| Chief Financial Officer | 5.6yrs | US$1.38m | 0.24% $ 6.3m | |
| Chief Medical Officer | 2.8yrs | US$1.57m | 0.24% $ 6.4m | |
| Chief Technical Operations Officer | no data | inga uppgifter | inga uppgifter | |
| Head of Investor Relations & Communications | no data | inga uppgifter | inga uppgifter | |
| Chief Legal Officer & General Counsel | 4.5yrs | US$2.30m | 0.030% $ 813.3k | |
| Chief Human Resources Officer | 2.5yrs | inga uppgifter | inga uppgifter | |
| Global Head of Regulatory Affairs | 6yrs | inga uppgifter | inga uppgifter | |
| VP & Head of Global Medical Affairs | 6.3yrs | inga uppgifter | inga uppgifter | |
| Head of Global Medical Strategy & Communications | no data | inga uppgifter | inga uppgifter | |
| Chief Commercial Officer | 1.6yrs | inga uppgifter | inga uppgifter |
5.6yrs
Genomsnittlig anställningstid
54yo
Genomsnittlig ålder
Erfaren ledning: AMLX s ledningsgrupp är erfaren och erfaren ( 5.6 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 12.6yrs | US$2.72m | 3.22% $ 86.7m | |
| Co-CEO & Director | 12.6yrs | US$2.72m | 3.22% $ 86.7m | |
| Special Advisor & Member of Advisory Board | 5.6yrs | US$51.24k | inga uppgifter | |
| Independent Chairman of the Board | 11.6yrs | US$218.58k | 0.73% $ 19.7m | |
| Chairman of The Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Director | 3.4yrs | US$161.08k | 0.060% $ 1.6m | |
| Independent Director | 5.2yrs | US$173.58k | 0.0045% $ 121.0k | |
| Independent Director | 2.4yrs | US$166.08k | 0.0090% $ 241.8k | |
| Independent Director | 5.4yrs | US$168.58k | 0.0036% $ 95.5k |
5.5yrs
Genomsnittlig anställningstid
65yo
Genomsnittlig ålder
Erfaren styrelse: AMLX s styrelse anses vara erfaren ( 5.5 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/07 21:42 |
| Aktiekurs vid dagens slut | 2026/08/07 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Amylyx Pharmaceuticals, Inc. bevakas av 12 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Christopher Chen | Baird |
| null null | Baird |
| Joel Beatty | Baird |